Business Context and Reporting Period
This Form 8-K Current Report from Biocardia, Inc. (BCDA) covers the event date of September 19, 2025. The filing details the consummation of a private placement offering of common stock and warrants to raise capital.
Key Financial Metrics and Transaction Details
- Securities Issued: 4,800,000 shares of Common Stock and accompanying warrants to purchase up to 4,800,000 shares.
- Offering Price: $1.25 per share and warrant.
- Gross Proceeds: Approximately $6.0 million (calculated as 4.8M units x $1.25).
- Net Proceeds: Approximately $5.1 million after deducting placement agent fees and offering expenses.
- Insider Participation: Directors and executive officers purchased 734,400 shares and warrants, representing approximately $0.9 million in gross proceeds.
- Warrant Terms: Exercise price of $1.25; immediately exercisable; expiration date of September 20, 2027.
Material Changes and Restrictions
The filing reports a material change in the company's capital structure due to the issuance of new equity. Key restrictions imposed by the Purchase Agreements include:
- Lock-Up Period: The Company agreed not to issue or announce the issuance of Common Stock (or convertible securities) through November 18, 2025, subject to exceptions for at-the-market offerings and Form S-8 filings.
- Variable Rate Transaction Prohibition: The Company is prohibited from entering into variable rate transactions through March 19, 2026, with specific exceptions for at-the-market offerings after November 18, 2025.
- Beneficial Ownership Limitation: Warrant holders are restricted from exercising warrants if it would result in beneficial ownership exceeding 4.99% (or 9.99% upon election) of outstanding shares.
Outlook, Risks, and Management Commentary
The filing does not provide forward-looking financial guidance, revenue projections, or specific management commentary regarding operational outlook. The primary focus is the execution of the capital raise. Risks associated with the transaction include potential dilution to existing shareholders and the restrictions on future capital raising activities during the lock-up periods.
Investor Verification Checklist
- Verify the final net proceeds of $5.1 million against the company's cash balance in subsequent filings.
- Confirm the exact number of shares outstanding post-offering to assess dilution impact.
- Monitor compliance with the lock-up restrictions ending November 18, 2025, and the variable rate transaction prohibition ending March 19, 2026.
- Review the full text of the Securities Purchase Agreement (Exhibit 99.1) for specific covenants and termination provisions.
- Check for any waivers of the lock-up or variable rate restrictions by the placement agent, H.C. Wainwright & Co., LLC.